HIV and COVID-19
Programmatic and clinical guidance
Interim guidance for COVID-19 and PLHIV (AIDSInfo): Review of special considerations for people living with HIV and their health care providers in the United States regarding COVID-19. The guidance offers suggestions on switching ART, appointment postponement, planning for isolation, and HIV SARS-CoV-2 co-infection management.
PEPFAR Technical Guidance in Context of COVID-19 Pandemic (PEPFAR): Technical note with guidance on a range of HIV-specific, cross-cutting and health systems issues related to PEPFAR's programmes. The document is updated twice per week as the situation evolves globally. See also:
- Draft tips and programmatic considerations for remote case management of orphans and vulnerable children (OVC Taskforce)
- Strategic considerations for mitigating the impact of COVID-19 on key-population-focused HIV programs (PEPFAR, USAID, EpiC)
Maintaining and prioritizing HIV prevention services in the time of COVID-19 (Global HIV Prevention Working Group): This brief outlines several critical actions and temporary modifications that can be considered to ensure continued effective HIV prevention and related services in the time of COVID-19.
Condoms and lubricants in the time of COVID-19. Sustaining supplies and people-centred approaches to meet the need in low- and middle-income countries (Global Condom Working Group): This brief for country condom programme managers and experts provides a summary of relevant actions to sustain supplies of male condoms, female condoms and lubricants, and to adjust approaches for condom promotion during the time of COVID-19.
PrEP during COVID-19 (CDC): US-based guidance for providing PrEP as an essential service when facility-based services and in-person patient-clinician contact is limited.
Models of COVID-19 impacts on HIV
The Potential Impact of the COVID-19 Epidemic on HIV, TB and Malaria in Low- and Middle-Income Countries (Imperial College London): Researchers have modelled the impact of COVID-19 on HIV, TB and malaria in low- and middle-income countries and predicted significant rises in cases and deaths. The greatest impact on HIV is estimated to be from interruption to supply and administering of ART; this could cause a 10 per cent rise in deaths over five years.
Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: Results from multiple mathematical models (Figshare): A modelling group convened by WHO and UNAIDS estimates that pandemic-related disruptions to HIV services for six months could cause more than 500,000 additional deaths from AIDS-related illnesses in subSaharan Africa in 2020–2021. Gains made in preventing mother-to-child HIV transmission could also be reversed.